Recurrence and Outcomes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children

OBJECTIVES: To report clinical course, etiology, management, and long-term outcomes of children suffering from Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). METHODS: We conducted a study of all pediatric patients with SJS or TEN admitted between 2000 and 2007 to the Hospital for Sick Children and Children's Hospital Boston, and particular attention was paid to clinical manifestations, etiology, mortality, and long-term outcomes. RESULTS: We identified 55 cases of SJS (n = 47), TEN (n = 5), or SJS/TEN overlap syndrome (n = 3). Drugs were identified as the most likely etiologic agent in 29 children (53%); antiepileptic drugs were the most common agents (n = 16), followed by sulfonamide antibiotics (n = 7) and chemotherapy drugs (n = 2). Acute Mycoplasma pneumoniae infection was confirmed in 12 children (22%), and herpes simplex virus was confirmed in 5 children (9%). Treatment regimens differed significantly between participating sites and included systemic antimicrobial agents (67%), systemic corticosteroids (40%), and antiviral drugs (31%). Intravenous immunoglobulin was administered to 21 children (38%), of whom 8 received concomitant systemic corticosteroids. Ten children (18%) had recurrence of SJS up to 7 years after the index episode, and 3 experienced multiple recurrences. Twenty-six children (47%) suffered long-term sequelae that mostly involved the skin and eyes. CONCLUSIONS: Mortality rate in children was lower than that reported in adults, but half of affected children suffered long-term complications. The recurrence rate of SJS was high (1 in 5), which suggests vulnerability and potential genetic predisposition. In the absence of standardized management guidelines for these conditions, treatment regimens differed significantly between participating institutions.

[1]  J. Roujeau,et al.  Open trial of ciclosporin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis , 2010, The British journal of dermatology.

[2]  A. Habib,et al.  Treatment of toxic epidermal necrolysis (TEN) with low dose intravenous immunoglobulin in child. , 2010, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[3]  S. Knowles,et al.  Clinical risk management of Stevens–Johnson syndrome/toxic epidermal necrolysis spectrum , 2009, Dermatologic therapy.

[4]  M. Koh,et al.  An update on Stevens–Johnson syndrome and toxic epidermal necrolysis in children , 2009, Current opinion in pediatrics.

[5]  A. Flahault,et al.  Medications as Risk Factors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children: A Pooled Analysis , 2009, Pediatrics.

[6]  Sheau-Fang Yang,et al.  Oxcarbazepine‐induced Stevens‐Johnson Syndrome: A Case Report , 2009, The Kaohsiung journal of medical sciences.

[7]  Yuan-Tsong Chen,et al.  Human leukocyte antigens and drug hypersensitivity , 2007, Current opinion in allergy and clinical immunology.

[8]  J. Roujeau,et al.  [Epidermal necrolysis: mechanisms of keratinocyte apoptosis]. , 2006, Medecine sciences : M/S.

[9]  Kristel Gélard,et al.  Nécrolyse épidermique : Mécanisme de l’apoptose des kératinocytes , 2006 .

[10]  R. Rawal,et al.  Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. , 2005, Indian journal of dermatology, venereology and leprology.

[11]  C. Rubino,et al.  Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. , 2005, British journal of plastic surgery.

[12]  J. Roujeau Clinical heterogeneity of drug hypersensitivity. , 2005, Toxicology.

[13]  M. Yoshita,et al.  MRI of segmental zoster paresis , 2005, Neurology.

[14]  D. Metry,et al.  Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. , 2003, Pediatrics.

[15]  R. Stern,et al.  The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. , 2003, The Journal of rheumatology.

[16]  J. Saffle,et al.  Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. , 2002, Journal of the American Academy of Dermatology.

[17]  A. Shetty,et al.  Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. , 2000, The Journal of rheumatology.

[18]  J. Roujeau,et al.  SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. , 2000, The Journal of investigative dermatology.

[19]  J. Huff,et al.  Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). , 1996, Journal of the American Academy of Dermatology.

[20]  M. Mockenhaupt,et al.  Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. , 1996, Journal of clinical epidemiology.

[21]  R. Stern,et al.  Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. , 1996, The New England journal of medicine.

[22]  L. Hughes-Davies,et al.  Severe adverse cutaneous reactions to drugs. , 1995, The New England journal of medicine.

[23]  S. Spielberg,et al.  Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. , 1988, The Journal of clinical investigation.

[24]  J. Gõmez Orbaneja,et al.  [Toxic epidermal necrolysis]. , 1967, Revista clinica espanola.

[25]  K. Shilkin,et al.  TOXIC EPIDERMAL NECROLYSIS (LYELL'S DISEASE) , 1966, Australian journal of dermatology.

[26]  D. Bandyopadhyay,et al.  Indian J Dermatol Venereol Leprol , 2010 .

[27]  M. Mockenhaupt,et al.  Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes , 2009, Intensive Care Medicine.

[28]  L. Naldi,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.

[29]  G. Koren,et al.  Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children , 2002, Drug safety.

[30]  M. Mockenhaupt,et al.  Cutaneous Adverse Drug Reactions , 2002 .

[31]  R. Stern,et al.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. , 1993, Archives of dermatology.

[32]  S. Jick,et al.  The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. , 1990, Archives of dermatology.

[33]  R. Stern,et al.  The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. , 1990 .